Novavax, Inc. (NASDAQ:NVAX) Stock Rated “Hold” by Wall Street Analysts

Novavax, Inc. (NASDAQ:NVAX) has been given an average rating of “Hold” by the nine brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $14.00.

Several analysts have issued reports on NVAX shares. Wall Street Zen upgraded Novavax from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Weiss Ratings reiterated a “sell (d)” rating on shares of Novavax in a research note on Tuesday, August 4th. Finally, Zacks Research lowered Novavax from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th.

Novavax Stock Performance

NASDAQ NVAX opened at $12.75 on Monday. The company has a market capitalization of $2.10 billion, a PE ratio of -8.39 and a beta of 2.44. Novavax has a 52-week low of $6.20 and a 52-week high of $13.39. The company has a 50-day simple moving average of $9.59 and a 200 day simple moving average of $9.10.

Novavax (NASDAQ:NVAX) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.06. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The firm had revenue of $56.70 million during the quarter, compared to the consensus estimate of $52.51 million. During the same period in the prior year, the firm earned $0.62 EPS. The company’s revenue was down 76.2% compared to the same quarter last year. As a group, analysts forecast that Novavax will post -0.48 EPS for the current fiscal year.

Novavax News Roundup

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Broad biotech rally: Vaccine and biotechnology stocks advanced, with Novavax among the strongest performers. Positive momentum across the sector likely attracted momentum traders and helped lift NVAX on unusually heavy volume. Novavax Soars, Moderna Surges, Merck Climbs as Biotech Rallies
• Positive Sentiment: Positive vaccine-sector sentiment: Moderna’s rally following reports of a planned national cancer-vaccine effort renewed investor interest in vaccine developers generally. Although the initiative is not a Novavax project, the enthusiasm may have benefited the broader vaccine group. Moderna Stock Hits 4-Year High on Planned National Cancer Vaccine Effort
• Positive Sentiment: Plague fears eased: Reports emphasizing the World Health Organization’s assessment that epidemic risk was low reduced a short-term source of uncertainty. Earlier headlines had driven sharp volatility in NVAX despite no direct change to the company’s vaccine portfolio. Novavax Headline-Driven Volatility Around Russia Health Scare
• Neutral Sentiment: Investor attention increased: Zacks reported elevated user interest in NVAX, but provided no new fundamental catalyst. Greater visibility can support trading activity while also increasing volatility. Novavax Is Attracting Investor Attention
• Negative Sentiment: Analyst remains cautious: BofA raised its price target to $8 from $7 but maintained an Underperform rating, indicating that the firm still views the recent share price as above its fundamental expectations. BofA Adjusts Price Target on Novavax
• Negative Sentiment: Fundamental and valuation risks: Commentary warned that the rebound may have moved NVAX above fair value, while Novavax’s longer-term growth prospects remain exposed to weak sales and execution risks. Novavax Vaccine Maker Sees Momentum in 2026 but Growth Story Holds Fundamental Risks

Hedge Funds Weigh In On Novavax

Large investors have recently modified their holdings of the business. KBC Group NV lifted its stake in shares of Novavax by 34.9% during the 1st quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 1,229 shares in the last quarter. Allworth Financial LP raised its holdings in Novavax by 292.5% during the 2nd quarter. Allworth Financial LP now owns 4,353 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 3,244 shares during the period. Duncker Streett & Co. Inc. raised its holdings in Novavax by 917.3% during the 1st quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 3,825 shares during the period. Abel Hall LLC lifted its position in shares of Novavax by 30.7% during the first quarter. Abel Hall LLC now owns 18,050 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 4,241 shares in the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Novavax in the second quarter worth $42,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc is a biotechnology company focused on the discovery, development and commercialization of vaccines. The company uses its recombinant protein-based vaccine platform and Matrix-M adjuvant technology to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is its protein-based COVID-19 vaccine, marketed in various regions under the Nuvaxovid or Novavax COVID-19 Vaccine name. The vaccine has been authorized or approved in multiple markets, including the United States, Europe and other international jurisdictions, with availability and regulatory status varying by country.